New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:30 EDTSYNSynthetic reports preclinical data to support clinical development of mAb
Synthetic Biologics announced positive preclinical research findings for SYN-005, the company's proprietary monoclonal antibody, or mAb, combination therapy for treating Pertussis. In the second pertussis study in particular, SYN-005 was associated with favorable decreases in white blood cell counts within two days and the achievement of nearly normal levels within one week. Based on positive non-human primate and murine model findings, Synthetic Biologics has filed an additional patent application around pertussis antibodies, intends to move into cGMP manufacturing of SYN-005, and intends to file an Investigational New Drug application to support a Phase I clinical trial expected to initiate during the first half of 2015. The Company also intends to request an Orphan Drug designation for SYN-005 for the treatment of Pertussis.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
13:22 EDTSYNSynthetic says Phase 2 Trimesta tral data published by lead investigator
Subscribe for More Information
November 24, 2015
06:59 EDTSYNSynthetic Biologics issued U.S. patent covering SYN-010
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use